Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

Presentation TCT 2019

A Randomized Trial of Short-Course Dual Antiplatelet Therapy vs. Oral Anticoagulation to Prevent Cerebral Embolism After Transcatheter Aortic Valve Implantation

Presenter: Victor Alfonso Dias

September 28, 2019

Debate: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients - Pro: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients

Presentation TCT 2019

Pro: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients

Presenter: C. Michael Gibson

September 27, 2019

Presentation TCT 2019

Final Words

Presenter: Roxana Mehran

September 26, 2019

Presentation TCT 2019

Take Home for Clinicians: DM and STEMI

Presenter: Dominick Angiolillo

September 26, 2019

Presentation TCT 2019

COMPLETE Trial: Focus on STEMI and MVD

Presenter: Shamir Mehta

September 26, 2019

Presentation TCT 2019

The Role of Antiplatelet Agents in Patients With Diabetes and Coronary Disease

Presenter: Marc Bonaca

September 26, 2019

Presentation TCT 2019

Take Home for Clinicians

Presenter: C. Michael Gibson

September 26, 2019

Presentation TCT 2019

Reconciling Adjudicated Data Within a Global Trial

Presenter: Marco Valgimigli

September 26, 2019

Presentation TCT 2019

Transitioning to Monotherapy in Patients After PCI

Presenter: Pascal Vranckx

September 26, 2019

Presentation TCT 2019

TWILIGHT: A Deep Dive

Presenter: Usman Baber

September 26, 2019

Presentation TCT 2019

Welcome and Introductions

Presenter: Roxana Mehran

September 26, 2019

Presentation ARCH 2019

Update on Dual Antiplatelet Therapy

Presenter: James B Hermiller

April 12, 2019

Presentation SIF 2019

Dual vs. Triple Therapy Post PCI Is There Really Any Debate?

Presenter: Jeffrey A Southard

March 29, 2019

Advertisement

A Randomized Trial of Short-Course Dual Antiplatelet Therapy vs. Oral Anticoagulation to Prevent Cerebral Embolism After Transcatheter Aortic Valve Implantation

Pro: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients

Final Words

Take Home for Clinicians: DM and STEMI

COMPLETE Trial: Focus on STEMI and MVD

The Role of Antiplatelet Agents in Patients With Diabetes and Coronary Disease

Take Home for Clinicians

Reconciling Adjudicated Data Within a Global Trial

Transitioning to Monotherapy in Patients After PCI

TWILIGHT: A Deep Dive

Welcome and Introductions

Update on Dual Antiplatelet Therapy

Dual vs. Triple Therapy Post PCI Is There Really Any Debate?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content